Eli Lilly Completes Acquisition of AtaiBeckley for Mental Health Innovations

INDIANAPOLIS, Sept. 11, 2026 /CourierPR/ -- Eli Lilly and Company has completed its acquisition of AtaiBeckley Inc., a clinical-stage biopharmaceutical company focused on developing rapid-acting neuroplastogens for mental health conditions. The deal marks a significant step forward in Lilly’s efforts to advance treatments for individuals suffering from treatment-resistant depression and other mental health disorders.

AtaiBeckley’s lead investigational program, BPL-003, is a neuroplastogen designed to offer a new paradigm in the treatment of mental health conditions. Carole Ho, executive vice president and president of Lilly Neuroscience, emphasized the potential of AtaiBeckley’s technology.

The acquisition was approved by AtaiBeckley shareholders at a special meeting held prior to the closing.

Lilly, known for its commitment to improving the lives of people around the world, has been at the forefront of medical innovation for over 150 years. The company’s diverse portfolio includes breakthroughs in diabetes care, obesity management, Alzheimer’s disease research, and the treatment of immune system disorders and cancers. With the addition of AtaiBeckley’s pipeline, Lilly aims to continue pushing the boundaries of what is possible in mental health treatment.

The acquisition reflects Lilly’s ongoing dedication to addressing the unmet needs of patients with treatment-resistant depression and other mental health conditions.

Lilly’s commitment to advancing neuroscience is evident in its continued investment in research and development. The company’s focus on patient-centric solutions underscores its mission to make a positive impact on global health. With the successful completion of this acquisition, Lilly is poised to make significant strides in the treatment of mental health conditions, offering new hope to those in need.